Evidence map›Paper›PMID 33971943›Full record

Observational studyClinical epigenetics2021

High-resolution targeted bisulfite sequencing reveals blood cell type-specific DNA methylation patterns in IL13 and ORMDL3.

Cilla Söderhäll, Lovisa E Reinius, Pertteli Salmenperä, Massimiliano Gentile, Nathalie Acevedo, Jon R Konradsen, Björn Nordlund, Gunilla Hedlin, Annika Scheynius, Samuel Myllykangas and 1 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Clinical epigenetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

Cilla SöderhällDepartment of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden. cilla.soderhall@ki.se.ORCID 0000-0002-8397-3080
Lovisa E ReiniusDepartment of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.
Pertteli SalmenperäBlueprint Genetics, Helsinki, Finland.
Massimiliano GentileBlueprint Genetics, Helsinki, Finland.
Nathalie AcevedoDepartment of Clinical Science and Education, Karolinska Institutet, and Sachs' Children and Youth Hospital, Södersjukhuset, 118 83, Stockholm, Sweden.
Jon R KonradsenDepartment of Women's and Children's Health, Karolinska Institutet, Bioclinicum J9:30, Visionsgatan 4, 171 64, Stockholm, Sweden.
Björn NordlundDepartment of Women's and Children's Health, Karolinska Institutet, Bioclinicum J9:30, Visionsgatan 4, 171 64, Stockholm, Sweden.
Gunilla HedlinDepartment of Women's and Children's Health, Karolinska Institutet, Bioclinicum J9:30, Visionsgatan 4, 171 64, Stockholm, Sweden.
Annika ScheyniusDepartment of Clinical Science and Education, Karolinska Institutet, and Sachs' Children and Youth Hospital, Södersjukhuset, 118 83, Stockholm, Sweden.
Samuel MyllykangasBlueprint Genetics, Helsinki, Finland.
Juha KereDepartment of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.
Karolinska University Hospital · SEBlueprint Genetics (Finland) · FIKarolinska Institutet · SEScience for Life Laboratory · SEUniversity of Cartagena · COUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMethylation of DNA at CpG sites is an epigenetic modification and a potential modifier of disease risk, possibly mediating environmental effects. Currently, DNA methylation is commonly assessed using specific microarrays that sample methylation at a few % of all methylated sites.

methodsTo understand if significant information on methylation can be added by a more comprehensive analysis of methylation, we set up a quantitative method, bisulfite oligonucleotide-selective sequencing (Bs-OS-seq), and compared the data with microarray-derived methylation data. We assessed methylation at two asthma-associated genes, IL13 and ORMDL3, in blood samples collected from children with and without asthma and fractionated white blood cell types from healthy adult controls.

resultsOur results show that Bs-OS-seq can uncover vast amounts of methylation variation not detected by commonly used array methods. We found that high-density methylation information from even one gene can delineate the main white blood cell lineages.

conclusionsWe conclude that high-resolution methylation studies can yield clinically important information at selected specific loci missed by array-based methods, with potential implications for future studies of methylation-disease associations.

Indexed as

AdolescentAdultCase-Control StudiesChildDNA MethylationEpigenesis, GeneticEpigenomicsFemaleHigh-Throughput Nucleotide SequencingHumansInterleukin-13MaleMembrane ProteinsSulfiteshydrogen sulfiteInterleukin-13Membrane ProteinsORMDL3 protein, humanSulfites450 kAsthmaBs-OS-sequencingCpG sitesDNA methylationEpigenetic profilingIL13ORMDL3

Identifiers

PMID33971943
PMCPMC8111952
OpenAlexW3163634426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.